Transforming blood test through technology innovation

As we enter the age of personalized medicine, DNA sequencing is playing an increasingly important role in determining a patient’s optimal treatment plan. Unfortunately, acquiring tumor to sequence often requires performing a tissue biopsy which can be painful, dangerous, and sometimes even impossible, as is the case with both metastatic and early stage cancer. Liquid biopsy, however, offers a viable non-invasive alternative to tissue biopsy. Not only is liquid biopsy minimally stressful for patients, but is also more comprehensive and easily performed at regular intervals. The potential applications of liquid biopsy are vast -- from targeted cancer therapy selection to real-time minimal residual disease monitoring to population-level early screening -- and we believe it will play a critical role in the future of cancer management.